D.A. Davidson & CO. Decreases Stock Position in Moderna, Inc. $MRNA

D.A. Davidson & CO. lowered its stake in Moderna, Inc. (NASDAQ:MRNA) by 33.7% in the 1st quarter, HoldingsChannel.com reports. The firm owned 55,397 shares of the company’s stock after selling 28,170 shares during the period. D.A. Davidson & CO.’s holdings in Moderna were worth $2,814,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently made changes to their positions in MRNA. New Mexico Educational Retirement Board grew its holdings in Moderna by 1.9% in the 4th quarter. New Mexico Educational Retirement Board now owns 15,700 shares of the company’s stock worth $463,000 after acquiring an additional 300 shares during the last quarter. Cromwell Holdings LLC raised its holdings in Moderna by 39.7% in the 4th quarter. Cromwell Holdings LLC now owns 1,200 shares of the company’s stock worth $35,000 after purchasing an additional 341 shares in the last quarter. IFP Advisors Inc lifted its position in shares of Moderna by 5.4% in the 4th quarter. IFP Advisors Inc now owns 6,785 shares of the company’s stock worth $200,000 after purchasing an additional 348 shares during the period. Empowered Funds LLC lifted its position in shares of Moderna by 2.6% in the 4th quarter. Empowered Funds LLC now owns 13,732 shares of the company’s stock worth $405,000 after purchasing an additional 353 shares during the period. Finally, Deseret Mutual Benefit Administrators boosted its stake in shares of Moderna by 16.9% during the 4th quarter. Deseret Mutual Benefit Administrators now owns 2,640 shares of the company’s stock valued at $78,000 after purchasing an additional 382 shares in the last quarter. Institutional investors own 75.33% of the company’s stock.

Insider Buying and Selling at Moderna

In other Moderna news, Director Abbas Hussain sold 5,682 shares of Moderna stock in a transaction on Friday, May 1st. The stock was sold at an average price of $46.63, for a total transaction of $264,951.66. Following the completion of the transaction, the director owned 12,066 shares in the company, valued at approximately $562,637.58. The trade was a 32.01% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, President Stephen Hoge sold 53,336 shares of the business’s stock in a transaction on Monday, June 15th. The stock was sold at an average price of $51.37, for a total value of $2,739,870.32. Following the completion of the sale, the president directly owned 1,483,848 shares in the company, valued at $76,225,271.76. This trade represents a 3.47% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 125,088 shares of company stock worth $6,193,713 over the last three months. Company insiders own 10.80% of the company’s stock.

Moderna Stock Performance

Shares of MRNA stock opened at $61.82 on Monday. The company’s fifty day moving average price is $57.87 and its 200-day moving average price is $50.95. The stock has a market cap of $24.53 billion, a PE ratio of -7.59 and a beta of 0.94. The company has a current ratio of 2.41, a quick ratio of 2.35 and a debt-to-equity ratio of 0.08. Moderna, Inc. has a 12 month low of $22.28 and a 12 month high of $85.60.

Moderna (NASDAQ:MRNA) last issued its quarterly earnings results on Friday, May 1st. The company reported ($3.40) earnings per share (EPS) for the quarter, missing the consensus estimate of ($3.02) by ($0.38). Moderna had a negative return on equity of 26.64% and a negative net margin of 143.55%.The business had revenue of $389.00 million during the quarter, compared to the consensus estimate of $236.37 million. During the same quarter in the previous year, the business earned ($2.52) earnings per share. The firm’s revenue was up 260.2% compared to the same quarter last year. On average, equities analysts expect that Moderna, Inc. will post -6.41 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several equities analysts recently issued reports on the stock. Barclays boosted their price target on shares of Moderna from $25.00 to $48.00 and gave the company an “equal weight” rating in a research report on Thursday, April 2nd. Weiss Ratings restated a “sell (d-)” rating on shares of Moderna in a report on Friday, June 12th. Morgan Stanley lifted their price objective on Moderna from $33.00 to $39.00 and gave the company an “equal weight” rating in a research report on Wednesday, July 8th. The Goldman Sachs Group upped their target price on Moderna from $43.00 to $49.00 and gave the stock a “neutral” rating in a report on Friday, May 1st. Finally, Royal Bank Of Canada increased their target price on Moderna from $38.00 to $45.00 and gave the stock a “sector perform” rating in a research report on Tuesday, July 7th. Two analysts have rated the stock with a Buy rating, ten have issued a Hold rating and five have assigned a Sell rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of “Reduce” and a consensus target price of $38.27.

Moderna Profile

Moderna, Inc is a biotechnology company headquartered in Cambridge, Massachusetts, specializing in messenger RNA (mRNA) therapeutics and vaccines. The company’s platform leverages synthetic mRNA to instruct cells to produce proteins that can prevent or treat diseases. Since its founding in 2010, Moderna has advanced from early-stage research into a broad pipeline of vaccine and therapeutic candidates designed to address infectious diseases, rare genetic disorders and chronic illnesses.

Moderna’s flagship product is its mRNA-based COVID-19 vaccine, which was the first of its kind to receive emergency use authorization and later full approval in multiple jurisdictions.